News

Enrollment activities at all 28 sites are now closed and no new patients will be accepted into the study. Randomization is expected to be completed in approximately 4

The Appeals court also dissolved the injunction preventing Actavis from further distribution of its generic version of Pulmicort Respules that was granted on March 12, 2015. "We are

Founded in 2005 by Myrtle Potter, Myrtle Potter & Company specializes in devising novel strategies to maximize the value of prescription drug brands and portfolios. "We have a

The acquisition of Hyperion occurred through a merger under Section 251(h) of the General Corporation Law of the State of Delaware following Horizon’s successful tender for 86% of

The studies, led by Moffitt researchers Heather Jim, PhD, Diane Portman, MD, Howard McLeod, PharmD, and Gillian Bell, PharmD will examine a number of genetic variants as predictors

Gen Ilac was granted the exclusive right to sell Iclusig as an investigational product in Turkey on a named-patient basis and will provide associated medical affairs and regulatory

Data also showed that there was a statistically significant survival benefit of 52% relative risk reduction of death or graft loss at 5 years post-transplant (hazard ratio=0.477, p=0.0045).

The trial has been named the "CLEAN-CF" trial which refers to "Clearing Lungs with ENaC inhibition in Cystic Fibrosis". The CLEAN-CF study will include CF patients regardless of

Stakeholders throughout the drug development enterprise have caught the patient centricity bug and it is highly contagious. Sponsors, CROs, investigative sites, technology solution and service vendors, and ethical